Antibody subclass deficiency accelerates tumorigenesis in genetically engineered mouse models of pancreatic cancer
JCI Insight · 08.07.2026 · 11 (13)
DOI: 10.1172/jci.insight.198489 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, online erschienen am 05.05.2026. Verfasst von Jeremy B Foote und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Carcinogenesis. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, UAB Intramural Grants.
Abstract (Originalsprache)
Antibody production by B cells has emerged as an important factor in regulating antitumor immunity with both suppressive and promotive roles in cancer. However, the specific effect of antibody deficiency during development of pancreatic ductal adenocarcinoma (PDAC) has not been explored. To address this question, we crossed the well-established KPC mouse model to mice lacking all circulating immunoglobulin (Ig) due to genetic ablation of both Ig secretion and Ig class switching (KPC-μSAID mice). KPC-μSAID mice exhibited a two-fold acceleration in tumor formation, a two-fold reduction in median survival, and increased liver metastases versus KPC-WT control mice. Immunofluorescence analysis of pancreatic tissues from antibody-sufficient KC- and KPC-WT mice showed that IgG was predominantly localized within the extracellular matrix (ECM). Furthermore, in both KC- and KPC-μSAID mice, ECM density and podoplanin + cancer-associated fibroblasts (CAFs) were significantly reduced. In the KPC-μSAID tumor microenvironment (TME), intratumoral myeloid-derived suppressor cells (MDSC) were also increased, while CD4 + and CD8 + T cells decreased, relative to tumor-bearing KPC-WT mice, with macrophage exhibiting a mixed polarization phenotype. These findings were recapitulated in antibody subclass–deficient, KPC-AID mice, suggesting a potentially novel function of IgG in suppressing PDAC progression by directly or indirectly regulating pancreatic fibrosis and the density of the ECM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology.
- Division of Hematology and Oncology, School of Medicine.
- Department of Pathology.
- Department of Genetics.
- Department of Biomedical Informatics and Data Science.
- Institute for Cancer Outcomes and Survivorship, and.
Förderung
- NCI NIH HHS
- NIH HHS
- UAB Intramural Grants
- NIH
Zitieren
APA
Foote, J. B., Sarvesh, S., Al Diffalha, S., Crossman, D. K., Cheng, C., Kim, M. H., Hardy, C., Carstens, J. L., Kojima, K., Rose, B. J., & Klug, C. A. (2026). Antibody subclass deficiency accelerates tumorigenesis in genetically engineered mouse models of pancreatic cancer. JCI Insight, 11(13). https://doi.org/10.1172/jci.insight.198489
Vancouver
Foote JB, Sarvesh S, Al Diffalha S, Crossman DK, Cheng C, Kim MH, et al. Antibody subclass deficiency accelerates tumorigenesis in genetically engineered mouse models of pancreatic cancer. JCI Insight. 2026;11(13). doi:10.1172/jci.insight.198489
BibTeX
@article{Foote2026,
author = {Foote, Jeremy B and Sarvesh, Sujith and Al Diffalha, Sameer and Crossman, David K and Cheng, Changde and Kim, Myung-Hee and Hardy, Cherlene and Carstens, Julienne L and Kojima, Kyoko and Rose, Bart J and Klug, Christopher A},
title = {Antibody subclass deficiency accelerates tumorigenesis in genetically engineered mouse models of pancreatic cancer},
journal = {JCI Insight},
year = {2026},
volume = {11},
number = {13},
doi = {10.1172/jci.insight.198489}
}
EUVIMED